Showing 151,061 - 151,080 results of 151,373 for search '"Pharmaceutical"', query time: 0.76s Refine Results
  1. 151061
  2. 151062
  3. 151063

    Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series by Yamamoto N, Tolcher A, Hafez N, Lugowska I, Ramlau R, Macarulla T, Geng J, Li J, Teufel M, Märten A, LoRusso P

    Published 2024-03-01
    “…Noboru Yamamoto,1 Anthony Tolcher,2 Navid Hafez,3,4 Iwona Lugowska,5 Rodryg Ramlau,6 Teresa Macarulla,7,8 Junxian Geng,9 Jian Li,9 Michael Teufel,9 Angela Märten,10 Patricia LoRusso3 1Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan; 2NEXT Oncology, San Antonio, TX, USA; 3Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA; 4The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, USA; 5Early Phase Clinical Trials Unit, Maria Skłodowska Curie National Research Institute of Oncology, Warsaw, Poland; 6Institute of Oncology, Poznan University of Medical Sciences, Poznan, Poland; 7Vall d’Hebrón University Hospital, Barcelona, Spain; 8Vall d’Hebrón Institute of Oncology (VHIO), Barcelona, Spain; 9Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 10Boehringer Ingelheim International GmbH, Ingelheim am Rhein, GermanyCorrespondence: Noboru Yamamoto, Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan, Tel + 81-3-3542-2511 ext 7319, Email nbryamam@ncc.go.jpBackground: In patients with advanced biliary tract cancer (BTC), first-line chemotherapy plus immunotherapy has improved outcomes; however, second-line options that reflect the disease’s molecular heterogeneity are still needed. …”
    Get full text
    Article
  4. 151064
  5. 151065
  6. 151066
  7. 151067
  8. 151068
  9. 151069
  10. 151070
  11. 151071
  12. 151072
  13. 151073
  14. 151074
  15. 151075
  16. 151076

    Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization by Corren J, Jackson DJ, Casale TB, Borish L, Rabe KF, Busse WW, Maspero JF, Jackson DJ, Daizadeh N, Altincatal A, Radwan A, Khodzhayev A, Djandji M, Jacob-Nara JA, Rowe PJ, Deniz Y

    Published 2023-03-01
    “…Jonathan Corren,1 David J Jackson,2,3 Thomas B Casale,4 Larry Borish,5,6 Klaus F Rabe,7,8 William W Busse,9 Jorge F Maspero,10 Daniel J Jackson,11 Nadia Daizadeh,12 Arman Altincatal,12 Amr Radwan,13 Angela Khodzhayev,13 Michel Djandji,12 Juby A Jacob-Nara,12,14 Paul J Rowe,14 Yamo Deniz13 1David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; 2King’s College London, London, UK; 3Guy’s and St Thomas’ NHS Foundation Trust, London, UK; 4Division of Allergy and Immunology, University of South Florida, Tampa, FL, USA; 5Asthma and Allergic Disease Center, University of Virginia Health System, Charlottesville, VA, USA; 6Carter Immunology Center, University of Virginia Health System, Charlottesville, VA, USA; 7LungenClinic Grosshansdorf (Member of the German Center for Lung Research [DZL]), Airway Research Center North (ARCN), Grosshansdorf, Germany; 8Christian-Albrechts University (Member of the German Center for Lung Research [DZL]), Airway Research Center North (ARCN), Kiel, Germany; 9UW Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; 10Fundación CIDEA, Buenos Aires, Argentina; 11University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; 12Sanofi, Cambridge, MA, USA; 13Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 14Sanofi, Bridgewater, NJ, USACorrespondence: Jonathan Corren, David Geffen School of Medicine at UCLA, 10780 Santa Monica Blvd., Suite 280, Los Angeles, CA, 90025, USA, Email jcorren@ucla.eduPurpose: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukins-4/-13, key and central drivers of type 2 (T2) inflammation in multiple diseases. …”
    Get full text
    Article
  17. 151077
  18. 151078
  19. 151079
  20. 151080